Prostap QT prolongation
The summary of product characteristics for Prostap (leuprorelin; Takeda) has been updated to warn that androgen deprivation therapy may prolong the QT interval, therefore patients with a history of QT prolongation, those with risk factors for QT prolongation and patients receiving drugs that might prolong QT interval should be assessed before starting treatment.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067428
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com